Next Article in Journal
Staphylococcal Superantigen (TSST-1) Mutant Analysis Reveals that T Cell Activation Is Required for Biological Effects in the Rabbit Including the Cytokine Storm
Next Article in Special Issue
Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy
Previous Article in Journal / Special Issue
SLT-VEGF Reduces Lung Metastases, Decreases Tumor Recurrence, and Improves Survival in an Orthotopic Melanoma Model
Toxins 2010, 2(9), 2258-2271; doi:10.3390/toxins2092258
Review

Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy

1,* , 2
 and 1
1 Department of Paediatric Orthopaedics, Centre for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany 2 Centre for physiotherapy and neurorehabilitation, Berlin, Germany
* Author to whom correspondence should be addressed.
Received: 23 July 2010 / Revised: 24 August 2010 / Accepted: 26 August 2010 / Published: 27 August 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [947 KB, uploaded 27 August 2010]   |   Browse Figures

Abstract

The treatment of children with cerebral palsy with Botulinum toxin A injections is well established, safe and effective. However, a standardized injection strategy is still missing and the used dosage has escalated over the years. In the recent past, the recommended dosages in Europe were, however, reduced due to a better understanding of the relationship between dosage, severe side effects and the kind of anesthesia used. To combine safety and efficacy, the trend tends to a lower dosage, but combined with a more specific selection of injected muscles. The treatment of these key-muscles takes into account the best support for motor development to attain each individual motor milestone.
Keywords: botulinum toxin A; cerebral palsy; CP; multi-level treatment; key-muscle concept botulinum toxin A; cerebral palsy; CP; multi-level treatment; key-muscle concept
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Placzek, R.; Siebold, D.; Funk, J.F. Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy. Toxins 2010, 2, 2258-2271.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert